Value of podoplanin as an immunohistochemical marker in tumor diagnosis: A review and update

Applied Immunohistochemistry and Molecular Morphology

Volumn 22, Issue 5, 2014, Pages 331-347

  Ordóñez, Nelson G ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

D2 40; Follicular dendritic cell tumor; Immunohistochemistry; Kaposi sarcoma; Lymphatic endothelium; Mesothelioma; Podoplanin; Seminoma

Indexed keywords

ANTIBODY; CELL MARKER; PODOPLANIN; PODOPLANIN ANTIBODY; TUMOR MARKER; UNCLASSIFIED DRUG; MEMBRANE PROTEIN; PDPN PROTEIN, HUMAN;

ARTICLE; BONE TUMOR; CARTILAGE TUMOR; CENTRAL NERVOUS SYSTEM TUMOR; ENDOTHELIUM CELL; FOLLICULAR DENDRITIC CELL; GONAD TUMOR; IMMUNOHISTOCHEMISTRY; MESOTHELIUM CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; SKIN TUMOR; SOFT TISSUE TUMOR; TUMOR CLASSIFICATION; TUMOR DIAGNOSIS; VASCULAR TUMOR; DIFFERENTIAL DIAGNOSIS; HUMAN; LYMPH VESSEL; MESOTHELIOMA; METABOLISM; NEOPLASMS, GERM CELL AND EMBRYONAL; NEOPLASMS, VASCULAR TISSUE; VASCULAR ENDOTHELIUM;

DIAGNOSIS, DIFFERENTIAL; ENDOTHELIUM, VASCULAR; HUMANS; IMMUNOHISTOCHEMISTRY; LYMPHATIC VESSELS; MEMBRANE GLYCOPROTEINS; MESOTHELIOMA; NEOPLASMS, GERM CELL AND EMBRYONAL; NEOPLASMS, VASCULAR TISSUE; TUMOR MARKERS, BIOLOGICAL;

EID: 84900477534     PISSN: 15412016     EISSN: 15334058     Source Type: Journal    
DOI: 10.1097/PAI.0b013e31828a83c5     Document Type: Article

References (188)

1. Nose K, Saito H, Kuroki T. Isolation of a gene sequence induced later by tumor-promoting 12-O-tetradecanoylphorbol-13-acetate in mouse osteoblastic cells (MC3T3-E1) and expressed constitutively in ras-transformed cells. Cell Growth Differ. 1990; 1: 511-518.
2. Wetterwald A, Hoffstetter W, Cecchini MG, et al. Characterization and cloning of the E11 antigen, a marker expressed by rat osteoblasts and osteocytes. Bone. 1996; 18: 125-132.
3. Rishi AK, Joyce-Brady M, Fisher J, et al. Cloning, characterization, and development expression of a rat lung alveolar type I cell gene in embryonic endodermal and neural derivatives. Dev Biol. 1995; 167: 294-306.
4. Gandarillas A, Scholl FG, Benito N, et al. Induction of PA2.26, a cell-surface antigen expressed by active fibroblasts, in mouse epidermal keratinocytes during carcinogenesis. Mol Carcinog. 1997; 20: 10-18.
5. Scholl FG, Gamallo C, VilaróS, et al. Identification of PA2.26 antigen as a novel cell-surface mucin-type glycoprotein that induces plasma membrane extensions and increased motility in keratinocytes. J Cell Sci. 1999; 112: 4601-4613.
6. Zimmer G, Klenk HD, Herrler G. Identification of a 40-kDa cell surface sialoglycoprotein with the characteristics of a major influenza C virus receptor in a Madin-Darby canine kidney cell line. J Biol Chem. 1995; 270: 17815-17822.
7. Kato Y, Fujita N, Kunita A, et al. Molecular identification of Aggrus/T1alpha as a platelet aggregation-inducing factor expressed in colorectal tumors. J Biol Chem. 2003; 278: 51599-51605.
8. Baumal R, Bailey D, Giwercman A, et al. A novel maturation marker for human Sertoli cells. Int J Androl. 1989; 12: 354-359.
9. Jorgensen N, Giwercman A, Müller J, et al. Immunohistochemical markers of carcinoma in situ of the testis also expressed in normal infantile germ cells. Histopathology. 1993; 22: 373-378.
10. Jorgensen N, Rajpert-De Meyts E, Graem N, et al. Expression of immunohistochemical markers for testicular carcinoma in situ by normal human fetal germ cells. Lab Invest. 1995; 72: 223-231.
11. Breiteneder-Geleff S, Matsui K, Soleiman A, et al. Podoplanin, novel 43-kd membrane protein of glomerular epithelial cells, is down-regulated in puromycin nephrosis. Am J Pathol. 1997; 151: 1141-1152.
12. Matsui K, Breiteneder-Geleff S, Kerjaschki D. Epitope-specific antibodies to the 43-kD glomerular membrane protein podoplanin cause proteinuria and rapid flattening of podocytes. J Am Soc Nephrol. 1998; 9: 2013-2026.
13. Kaneko MK, Kato Y, Kitano T, et al. Conservation of a platelet activating domain of Aggrus/podoplanin as a platelet aggregationinducing factor. Gene. 2006; 378: 52-57.
14. Kriehuber E, Breiteneder-Geleff S, Groeger M, et al. Isolation and characterization of dermal lymphatic and blood endothelial cells reveal stable and functionally specialized cell lineages. J Exp Med. 2001; 194: 797-808.
15. Hong YK, Harvey N, Noh YH, et al. Prox1 is a master control gene in the program specifying lymphatic endothelial cell fate. Dev Dyn. 2002; 225: 351-357.
16. Hirakawa S, Hong YK, Harvey N, et al. Identification of vascular lineage-specific genes by transcriptional profiling of isolated blood vascular and lymphatic endothelial cells. Am J Pathol. 2003; 162: 575-586.
17. Ramirez MI, Millien G, Hinds A, et al. T1alpha, a lung type I cell differentiation gene, is required for normal lung cell proliferation and alveolus formation at birth. Dev Biol. 2003; 256: 61-72.
18. Schacht V, Ramirez MI, Hong YK, et al. T1alpha/podoplanin deficiency disrupts normal lymphatic vasculature formation and causes lymphedema. EMBO J. 2003; 22: 3546-3556.
19. Schacht V, Dadras SS, Johnson LA, et al. Up-regulation of the lymphatic marker podoplanin, a mucin-type transmembrane glycoprotein, in human squamous cell carcinomas and germ cell tumors. Am J Pathol. 2005; 166: 913-921.
20. Kunita A, Kashima TG, Morishita Y, et al. The platelet aggregation-inducing factor aggrus/podoplanin promotes pulmonary metastasis. Am J Pathol. 2007; 170: 1337-1347.
21. Wicki A, Christofori G. The potential role of podoplanin in tumour invasion. Br J Cancer. 2007; 96: 1-5.
22. Zimmer G, Oeffner F, Von Messling V, et al. Cloning and characterization of gp36, a human mucin-type glycoprotein preferentially expressed in vascular endothelium. Biochem J. 1999; 341: 277-284.
23. Chu AY, Litzky LA, Pasha TL, et al. Utility of D2-40, a novel mesothelial marker, in the diagnosis of malignant mesothelioma. Mod Pathol. 2005; 18: 105-110.
24. Ordóñez NG. D2-40 and podoplanin are highly specific and sensitive immunohistochemical markers of epithelioid malignant mesothelioma. Hum Pathol. 2005; 36: 372-380.
25. Ordóñez NG. Podoplanin: a novel diagnostic immunohistochemical marker. Adv Anat Pathol. 2006; 13: 83-88.
26. Williams MC, Cao Y, Hinds A, et al. T1 alpha protein is developmentally regulated and expressed by alveolar type I cells, choroid plexus, and ciliary epithelia of adult rats. Am J Respir Cell Mol Biol. 1996; 14: 577-585.
27. Zhang K, Barragan-Adjemian C, Ye L, et al. E11/gp38 selective expression in osteocytes: regulation by mechanical strain and role in dendrite elongation. Mol Cell Biol. 2006; 26: 4539-4552.
28. Hantusch B, Kalt R, Krieger S, et al. Sp1/Sp3 and DNA-methylation contribute to basal transcriptional activation of human podoplanin in MG63 versus Saos-2 osteoblastic cells. BMC Mol Biol. 2007; 8: 20.
29. Ariizumi T, Ogose A, Kawashima H, et al. Expression of podoplanin in human bone and bone tumors: new marker of osteogenic and chondrogenic bone tumors. Pathol Int. 2010; 60: 193-202.
30. Kashima TG, Dongre A, Flanagan AM, et al. Podoplanin expression in adamantinoma of long bones and osteofibrous dysplasia. Virchows Arch. 2011; 459: 41-46.
31. Yu H, Gibson JA, Pinkus GS, et al. Podoplanin (D2-40) is a novel marker for follicular dendritic cell tumors. Am J Clin Pathol. 2007; 128: 776-782.
32. Xie Q, Chen L, Fu K, et al. Podoplanin (d2-40): a new immunohistochemical marker for reactive follicular dendritic cells and follicular dendritic cell sarcomas. Int J Clin Exp Pathol. 2008; 1: 276-284.
33. Marsee DK, Pinkus GS, Hornick JL. Podoplanin (D2-40) is a highly effective marker of follicular dendritic cells. Appl Immunohistochem Mol Morphol. 2009; 17: 102-107.
34. Kuroda N, Tanida N, Oonishi K, et al. Significance of D2-40 expression in the diagnosis of gastrointestinal stromal tumor. Med Mol Morphol. 2008; 41: 109-112.
35. Nakamura Y, Kanemura Y, Yamada T, et al. D2-40 antibody immunoreactivity in developing human brain, brain tumors and cultured neural cells. Mod Pathol. 2006; 19: 974-985.
36. Marks A, Sutherland DR, Bailey D, et al. Characterization and distribution of an oncofetal antigen (M2A antigen) expressed on testicular germ cell tumours. Br J Cancer. 1999; 80: 569-578.
37. Kanner WA, Galgano MT, Atkins KA. Podoplanin expression in basal and myoepithelial cells: utility and potential pitfalls. Appl Immunohistochem Mol Morphol. 2010; 18: 226-230.
38. Ren S, Abuel-Haija M, Khurana JS, et al. D2-40: an additional marker for myoepithelial cells of breast and the precaution in interpreting tumor lymphovascular invasion. Int J Clin Exp Pathol. 2011; 4: 175-182.
39. Wu HM, Ren GX, Wang LZ, et al. Expression of podoplanin in salivary gland adenoid cystic carcinoma and its association with distant metastasis and clinical outcomes. Mol Med Report. 2012; 6: 271-274.
40. Gomaa AH, Yaar M, Bhawan J. Cutaneous immunoreactivity of D2-40 antibody beyond the lymphatics. Am J Dermatopathol. 2007; 29: 18-21.
41. Liang H, Wu H, Giorgadze TA, et al. Podoplanin is a highly sensitive and specific marker to distinguish primary skin adnexal carcinomas from adenocarcinomas metastatic to skin. Am J Surg Pathol. 2007; 31: 304-310.
42. Yang HM, Cabral E, Dadras SS, et al. Immunohistochemical expression of D2-40 in benign and malignant sebaceous tumors and comparison to basal and squamous cell carcinomas. Am J Dermatopathol. 2008; 30: 549-554.
43. Raica M, Kondylis A, Mogoanta L, et al. Diagnostic and clinical significance of D2-40 expression in the normal human thymus and thymoma. Rom J Morphol Embryol. 2010; 51: 229-234.
44. Aishima S, Nishihara Y, Iguchi T, et al. Lymphatic spread is related to VEGF-C expression and D2-40-positive myofibroblasts in intrahepatic cholangiocarcinoma. Mod Pathol. 2008; 21: 256-264.
45. Sonne SB, Herlihy AS, Hoei-Hansen CE, et al. Identity of M2A (D2-40) antigen and gp36 (Aggrus, T1A-2, podoplanin) in human developing testis, testicular carcinoma in situ and germ-cell tumours. Virchows Arch. 2006; 449: 200-206.
46. Ordóñez NG, Batsakis JG. Comparison of Ulex europaeus I lectin and factor VIII-related antigen in vascular lesions. Arch Pathol Lab Med. 1984; 108: 129-132.
47. Ordóñez NG. Immunohistochemical endothelial markers: a review. Adv Anat Pathol. 2012; 19: 281-295.
48. Birner P, Obermair A, Schindl M, et al. Selective immunohistochemical staining of blood and lymphatic vessels reveals independent prognostic influence of blood and lymphatic vessel invasion in early-stage cervical cancer. Clin Cancer Res. 2001; 7: 93-97.
49. Cunnick GH, Jiang WG, Gomez KF, et al. Lymphangiogenesis and breast cancer metastasis. Histol Histopathol. 2002; 17: 863-870.
50. Sedivy R, Beck-Mannagetta J, Haverkampf C, et al. Expression of vascular endothelial growth factor-C correlates with the lymphatic microvessel density and the nodal status in oral squamous cell cancer. J Oral Pathol Med. 2003; 32: 455-460.
51. Straume O, Jackson DG, Akslen LA. Independent prognostic impact of lymphatic vessel density and presence of low-grade lymphangiogenesis in cutaneous melanoma. Clin Cancer Res. 2003; 9: 250-256.
52. Dadras SS, North PE, Bertoncini J, et al. Infantile hemangiomas are arrested in an early developmental vascular differentiation state. Mod Pathol. 2004; 17: 1068-1079.
53. Kahn HJ, Marks A. A new monoclonal antibody, D2-40, for detection of lymphatic invasion in primary tumors. Lab Invest. 2002; 82: 1255-1257.
54. Dumoff KL, Chu C, Xu X, et al. Low D2-40 immunoreactivity correlates with lymphatic invasion and nodal metastasis in earlystage squamous cell carcinoma of the uterine cervix. Mod Pathol. 2005; 18: 97-104.
55. Schmid K, Birner P, Gravenhorst V, et al. Prognostic value of lymphatic and blood vessel invasion in neuroendocrine tumors of the lung. Am J Surg Pathol. 2005; 29: 324-328.
56. Breiteneder-Geleff S, Soleiman A, Kowalski H, et al. Angiosarcomas express mixed endothelial phenotypes of blood and lymphatic capillaries: podoplanin as a specific marker for lymphatic endothelium. Am J Pathol. 1999; 154: 385-394.
57. Sinzelle E, Duong Van Huyen JP, Breiteneder-Geleff S, et al. Intrapericardial lymphangioma with podoplanin immunohistochemical characterization of lymphatic endothelial cells. Histopathology. 2000; 37: 93-94.
58. Franke FE, Steger K, Marks A, et al. Hobnail hemangiomas (targetoid hemosiderotic hemangiomas) are true lymphangiomas. J Cutan Pathol. 2004; 31: 362-367.
59. Debelenko LV, Perez-Atayde AR, Mulliken JB, et al. D2-40 immunohistochemical analysis of pediatric vascular tumors reveals positivity in kaposiform hemangioendothelioma. Mod Pathol. 2005; 18: 1454-1460.
60. Arai E, Kuramochi A, Tsuchida T, et al. Usefulness of D2-40 immunohistochemistry for differentiation between kaposiform hemangioendothelioma and tufted angioma. J Cutan Pathol. 2006; 33: 492-497.
61. Hansen T, Katenkamp K, Bittinger F, et al. D2-40 labeling in lymphangiomyoma/lymphangiomyomatosis of the soft tissue: further evidence of lymphangiogenic tumor histogenesis. Virchows Arch. 2007; 450: 449-453.
62. Naqvi J, Ordóñez NG, Luna MA, et al. Epithelioid hemangioendothelioma of the head and neck: role of podoplanin in the differential diagnosis. Head Neck Pathol. 2008; 2: 25-30.
63. Le Huu AR, Jokinen CH, Rubin BP, et al. Expression of prox1, lymphatic endothelial nuclear transcription factor, in Kaposiform hemangioendothelioma and tufted angioma. Am J Surg Pathol. 2010; 34: 1563-1573.
64. Miettinen M, Wang ZF. Prox1 transcription factor as a marker for vascular tumors-evaluation of 314 vascular endothelial and 1086 nonvascular tumors. Am J Surg Pathol. 2012; 36: 351-359.
65. Nguyen VA, Kutzner H, Fürhapter C, et al. Infantile hemangioma is a proliferation of LYVE-1-negative blood endothelial cells without lymphatic competence. Mod Pathol. 2006; 19: 291-298.
66. Pyakurel P, Pak F, Mwakigonja AR, et al. Lymphatic and vascular origin of Kaposi's sarcoma spindle cells during tumor development. Int J Cancer. 2006; 119: 1262-1267.
67. Fanburg-Smith JC, Michal M, Partanen TA, et al. Papillary intralymphatic angioendothelioma (PILA): a report of twelve cases of a distinctive vascular tumor with phenotypic features of lymphatic vessels. Am J Surg Pathol. 1999; 23: 1004-1010.
68. Partanen TA, Alitalo K, Miettinen M. Lack of lymphatic vascular specificity of vascular endothelial growth factor receptor 3 in 185 vascular tumors. Cancer. 1999; 86: 2406-2412.
69. Weninger W, Partanen TA, Breiteneder-Geleff S, et al. Expression of vascular endothelial growth factor receptor-3 and podoplanin suggests a lymphatic endothelial cell origin of Kaposi's sarcoma tumor cells. Lab Invest. 1999; 79: 243-251.
70. Folpe AL, Veikkola T, Valtola R, et al. Vascular endothelial growth factor receptor-3 (VEGFR-3): a marker of vascular tumors with presumed lymphatic differentiation, including Kaposi's sarcoma, kaposiform and Dabska-type hemangioendotheliomas, and a subset of angiosarcomas. Mod Pathol. 2000; 13: 180-185.
71. Neuhauser TS, Derringer GA, Thompson LD, et al. Splenic angiosarcoma: a clinicopathologic and immunophenotypic study of 28 cases. Mod Pathol. 2000; 13: 978-987.
72. Itakura E, Yamamoto H, Oda Y, et al. VEGF-C and VEGFR-3 in a series of lymphangiomas: is superficial lymphangioma a true lymphangioma? Virchows Arch. 2009; 454: 317-325.
73. Saito M, Gunji Y, Kashii Y, et al. Refractory kaposiform hemangioendothelioma that expressed vascular endothelial growth factor receptor (VEGFR)-2 and VEGFR-3: a case report. J Pediatr Hematol Oncol. 2009; 31: 194-197.
74. Tokuyama W, Mikami T, Masuzawa M, et al. Autocrine and paracrine roles of VEGF/VEGFR-2 and VEGF-C/VEGFR-3 signaling in angiosarcomas of the scalp and face. Hum Pathol. 2010; 41: 407-414.
75. Valtola R, Salven P, Heikkilä P, et al. VEGFR-3 and its ligand VEGF-C are associated with angiogenesis in breast cancer. Am J Pathol. 1999; 154: 1381-1390.
76. Kahn HJ, Bailey D, Marks A. Monoclonal antibody D2-40, a new marker of lymphatic endothelium, reacts with Kaposi's sarcoma and a subset of angiosarcomas. Mod Pathol. 2002; 15: 434-440.
77. Fukunaga M. Expression of D2-40 in lymphatic endothelium of normal tissues and in vascular tumours. Histopathology. 2005; 46: 396-402.
78. Hornick JL, Fletcher CD. Intraabdominal cystic lymphangiomas obscured by marked superimposed reactive changes: clinicopathological analysis of a series. Hum Pathol. 2005; 36: 426-432.
79. Fujii T, Zen Y, Sato Y, et al. Podoplanin is a useful diagnostic marker for epithelioid hemangioendothelioma of the liver. Mod Pathol. 2008; 21: 125-130.
80. Guarda LG, Silva EG, Ordóñez NG, et al. Factor VIII in Kaposi's sarcoma. Am J Clin Pathol. 1981; 76: 197-200.
81. Aziza J, Mazerolles C, Selves J, et al. Comparison of the reactivities of monoclonal antibodies QBEND10 (CD34) and BNH9 in vascular tumors. Appl Immunohistochem. 1993; 1: 51-57.
82. Russell Jones R, Orchard G, Zelger B, et al. Immunostaining for CD31 and CD34 in Kaposi sarcoma. J Clin Pathol. 1995; 48: 1011-1016.
83. Lymboussaki A, Partanen TA, Olofsson B, et al. Expression of the vascular endothelial growth factor C receptor VEGFR-3 in lymphatic endothelium of the skin and in vascular tumors. Am J Pathol. 1998; 153: 395-403.
84. Nunes Rosado FG, Itani DM, Coffin CM, et al. Utility of immunohistochemical staining with FLI1, D2-40, CD31, and CD34 in the diagnosis of acquired immunodeficiency syndromerelated and non-acquired immunodeficiency syndrome-related Kaposi sarcoma. Arch Pathol Lab Med. 2012; 136: 301-304.
85. Zukerberg LR, Nickoloff BJ, Weiss SW. Kaposiform hemangioendothelioma of infancy and childhood. An aggressive neoplasm associated with Kasabach-Merritt syndrome and lymphangiomatosis. Am J Surg Pathol. 1993; 17: 321-328.
86. Hu B, Lachman R, Phillips J, et al. Kasabach-Merritt syndromeassociated kaposiform hemangioendothelioma successfully treated with cyclophosphamide, vincristine, and actinomycin D. J Pediatr Hematol Oncol. 1998; 20: 567-569.
87. Vin-Christian K, McCalmont TH, Frieden IJ. Kaposiform hemangioendothelioma. An aggressive, locally invasive vascular tumor that can mimic hemangioma of infancy. Arch Dermatol. 1997; 133: 1573-1578.
88. Parsons A, Sheehan DJ, Sangueza OP. Retiform hemangioendotheliomas usually do not express D2-40 and VEGFR-3. Am J Dermatopathol. 2008; 30: 31-33.
89. Emberger M, Laimer M, Steiner H, et al. Retiform hemangioendothelioma: presentation of a case expressing D2-40. J Cutan Pathol. 2009; 36: 987-990.
90. Albertini AF, Brousse N, Bodemer C, et al. Retiform hemangioendothelioma developed on the site of an earlier cystic lymphangioma in a six-year-old girl. Am J Dermatopathol. 2011; 33: e84-e87.
91. Hansen T, Katenkamp K, Katenkamp D. D2-40 staining in sinonasal-type hemangiopericytoma-further evidence of distinction from conventional hemangiopericytoma and solitary fibrous tumor. Virchows Arch. 2006; 448: 459-462.
92. Sadeghpour M, Antaya RJ, Lazova R, et al. Dilated lymphatic vessels in tufted angioma: a potential source of diagnostic confusion. Am J Dermatopathol. 2012; 34: 400-403.
93. Ge Y, Ro JY, Kim D, et al. Clinicopathologic and immunohistochemical characteristics of adult primary cardiac angiosarcomas: analysis of 10 cases. Ann Diagn Pathol. 2011; 15: 262-267.
94. Requena L, Santonja C, Stutz N, et al. Pseudolymphomatous cutaneous angiosarcoma: a rare variant of cutaneous angiosarcoma readily mistaken for cutaneous lymphoma. Am J Dermatopathol. 2007; 29: 342-350.
95. Suurmeijer AJ, Fletcher CD. Papillary haemangioma. A distinctive cutaneous haemangioma of the head and neck area containing eosinophilic hyaline globules. Histopathology. 2007; 51: 638-648.
96. Kimura N, Kimura I. Podoplanin as a marker for mesothelioma. Pathol Int. 2005; 55: 83-86.
97. Ordóñez NG. Mesotheliomas with small cell features: report of eight cases. Mod Pathol. 2012; 25: 689-698.
98. Ordóñez NG. Mesothelioma with signet-ring cell features: report of 23 cases. Mod Pathol. 2012. [Epub ahead of print].
99. Sienko A, Zander DS, Killen D, et al. D2-40 is a novel new marker of malignant mesothelioma (MM): tissue microarray study of 45 MM versus 409 lung carcinomas and primary non-mesothelial neoplasms of the pleura and chest wall [abstract]. Mod Pathol. 2005; 18(suppl. 1): 318A.
100. Müller AM, Franke FE, Müller KM. D2-40: a reliable marker in the diagnosis of pleural mesothelioma. Pathobiology. 2006; 73: 50-54.
101. Hinterberger M, Reineke T, Storz M, et al. D2-40 and calretinin- a tissue microarray analysis of 341 malignant mesotheliomas with emphasis on sarcomatoid differentiation. Mod Pathol. 2007; 20: 248-255.
102. Mimura T, Ito A, Sakuma T, et al. Novel marker D2-40, combined with calretinin, CEA, and TTF-1: an optimal set of immunodiagnostic markers for pleural mesothelioma. Cancer. 2007; 109: 933-938.
103. Padgett DM, Cathro HP, Wick MR, et al. Podoplanin is a better immunohistochemical marker for sarcomatoid mesothelioma than calretinin. Am J Surg Pathol. 2008; 32: 123-127.
104. Amatya VJ, Takeshima Y, Kohno H, et al. Caveolin-1 is a novel immunohistochemical marker to differentiate epithelioid mesothelioma from lung adenocarcinoma. Histopathology. 2009; 55: 10-19.
105. Hu Y, Yang Q, McMahon LA, et al. Value of D2-40 in the differential diagnosis of pleural neoplasms with emphasis on its positivity in solitary fibrous tumor. Appl Immunohistochem Mol Morphol. 2010; 18: 411-413.
106. Kato Y, Kaneko M, Sata M, et al. Enhanced expression of Aggrus (T1alpha/podoplanin), a platelet-aggregation-inducing factor in lung squamous cell carcinoma. Tumour Biol. 2005; 26: 195-200.
107. Deniz H, Kibar Y, Güldür ME, et al. Is D2-40 a useful marker for distinguishing malignant mesothelioma from pulmonary adenocarcinoma and benign mesothelial proliferations? Pathol Res Pract. 2009; 205: 749-752.
108. Min KH, Park SJ, Lee KS, et al. Clinical usefulness of D2-40 in non-small cell lung cancer. Lung. 2011; 189: 57-63.
109. Ordóñez NG. Value of calretinin immunostaining in differentiating epithelial mesothelioma from lung adenocarcinoma. Mod Pathol. 1998; 11: 929-933.
110. Ordóñez NG. The immunohistochemical diagnosis of mesothelioma: a comparative study of epithelioid mesothelioma and lung adenocarcinoma. Am J Surg Pathol. 2003; 27: 1031-1051.
111. Ordóñez NG. Pleomorphic mesothelioma: report of 10 cases. Mod Pathol. 2012; 25: 1011-1022.
112. Ordóñez NG. Deciduoid mesothelioma: report of 21 cases with review of the literature. Mod Pathol. 2012; 25: 1481-1495.
113. Doglioni C, Dei Tos AP, Laurino L, et al. Calretinin: a novel immunocytochemical marker for mesothelioma. Am J Surg Pathol. 1996; 20: 1037-1046.
114. Carella R, Deleonardi G, D'Errico A, et al. Immunohistochemical panels for differentiating epithelial malignant mesothelioma from lung adenocarcinoma: a study with logistic regression analysis. Am J Surg Pathol. 2001; 25: 43-50.
115. Comin CE, Novelli L, Boddi V, et al. Calretinin, thrombomodulin, CEA, and CD15: a useful combination of immunohistochemical markers for differentiating pleural epithelial mesothelioma from peripheral pulmonary adenocarcinoma. Hum Pathol. 2001; 32: 529-536.
116. Abutaily AS, Addis BJ, Roche WR. Immunohistochemistry in the distinction between malignant mesothelioma and pulmonary adenocarcinoma: a critical evaluation of new antibodies. J Clin Pathol. 2002; 55: 662-668.
117. Miettinen M, Sarlomo-Rikala M. Expression of calretinin, thrombomodulin, keratin 5, and mesothelin in lung carcinomas of different types: an immunohistochemical analysis of 596 tumors in comparison with epithelioid mesotheliomas of the pleura. Am J Surg Pathol. 2003; 27: 150-158.
118. Granville LA, Younes M, Churg A, et al. Comparison of monoclonal versus polyclonal calretinin antibodies for immunohistochemical diagnosis of malignant mesothelioma. Appl Immunohistochem Mol Morphol. 2005; 13: 75-79.
119. Ordóñez NG. The diagnostic utility of immunohistochemistry in distinguishing between epithelioid mesotheliomas and squamous carcinomas of the lung: a comparative study. Mod Pathol. 2006; 19: 417-428.
120. Shimada Y, Ishii G, Nagai K, et al. Expression of podoplanin, CD44, and p63 in squamous cell carcinoma of the lung. Cancer Sci. 2009; 100: 2054-2059.
121. Ordóñez NG. The diagnostic utility of immunohistochemistry and electron microscopy in distinguishing between peritoneal mesotheliomas and serous carcinomas: a comparative study. Mod Pathol. 2006; 19: 34-48.
122. Comin CE, Saieva C, Messerini L. h-caldesmon, calretinin, estrogen receptor, and Ber-EP4: a useful combination of immunohistochemical markers for differentiating epithelioid peritoneal mesothelioma from serous papillary carcinoma of the ovary. Am J Surg Pathol. 2007; 31: 1139-1148.
123. Nofech-Mozes S, Khalifa MA, Ismiil N, et al. Immunophenotyping of serous carcinoma of the female genital tract. Mod Pathol. 2008; 21: 1147-1155.
124. Takeshima Y, Amatya VJ, Kushitani K, et al. A useful antibody panel for differential diagnosis between peritoneal mesothelioma and ovarian serous carcinoma in Japanese cases. Am J Clin Pathol. 2008; 130: 771-779.
125. Attanoos RL, Dojcinov SD, Webb R, et al. Anti-mesothelial markers in sarcomatoid mesothelioma and other spindle cell neoplasms. Histopathology. 2000; 37: 224-231.
126. Lucas DR, Pass HI, Madan SK, et al. Sarcomatoid mesothelioma and its histological mimics: a comparative immunohistochemical study. Histopathology. 2003; 42: 270-279.
127. Kushitani K, Takeshima Y, Amatya VJ, et al. Differential diagnosis of sarcomatoid mesothelioma from true sarcoma and sarcomatoid carcinoma using immunohistochemistry. Pathol Int. 2008; 58: 75-83.
128. Takeshima Y, Amatya VJ, Kushitani K, et al. Value of immunohistochemistry in the differential diagnosis of pleural sarcomatoid mesothelioma from lung sarcomatoid carcinoma. Histopathology. 2009; 54: 667-676.
129. Sangoi AR, McKenney JK, Schwartz EJ, et al. Adenomatoid tumors of the female and male genital tracts: a clinicopathological and immunohistochemical study of 44 cases. Mod Pathol. 2009; 22: 1228-1235.
130. Wachter DL, Wünsch PH, Hartmann A, et al. Adenomatoid tumors of the female and male genital tract. A comparative clinicopathologic and immunohistochemical analysis of 47 cases emphasizing their site-specific morphologic diversity. Virchows Arch. 2011; 458: 593-602.
131. Terada T. An immunohistochemical study of adenomatoid tumors of the uterus and fallopian tube. Appl Immunohistochem Mol Morphol. 2012; 20: 173-176.
132. Bailey D, Marks A, Stratis M, et al. Immunohistochemical staining of germ cell tumors and intratubular malignant germ cells of the testis using antibody to placental alkaline phosphatase and a monoclonal anti-seminoma antibody. Mod Pathol. 1991; 4: 167-171.
133. Kato Y, Sasagawa I, Kaneko M, et al. Aggrus: a diagnostic marker that distinguishes seminoma from embryonal carcinoma in testicular germ cell tumors. Oncogene. 2004; 23: 8552-8556.
134. Biermann K, Klingmüller D, Koch A, et al. Diagnostic value of markers M2A, OCT3/4, AP-2gamma, PLAP and c-KIT in the detection of extragonadal seminomas. Histopathology. 2006; 49: 290-297.
135. Lau SK, Weiss LM, Chu PG. D2-40 immunohistochemistry in the differential diagnosis of seminoma and embryonal carcinoma: a comparative immunohistochemical study with KIT (CD117) and CD30. Mod Pathol. 2007; 20: 320-325.
136. Yu H, Pinkus GS, Hornick JL. Diffuse membranous immunoreactivity for podoplanin (D2-40) distinguishes primary and metastatic seminomas from other germ cell tumors and metastatic neoplasms. Am J Clin Pathol. 2007; 128: 767-775.
137. Sesterhenn IA, Davis CJ, Furusato B. M2A antigen (podoplanin) distribution in prepubertal and adult testes and testicular tumors [abstract]. Mod Pathol. 2006; 19(suppl 1): 159A-160A.
138. Esber CM, Shabsigh A, Zynger DL. Sclerosing Sertoli cell tumor without expression of typical sex cord stromal tumor markers: case report and literature review. Pathol Res Pract. 2012; 208: 121-125.
139. Chang MC, Vargas SO, Hornick JL, et al. Embryonic stem cell transcription factors and D2-40 (podoplanin) as diagnostic immunohistochemical markers in ovarian germ cell tumors. Int J Gynecol Pathol. 2009; 28: 347-355.
140. Oe S, Hasegawa K, Nagase S, et al. Expression of podoplanin in epithelial ovarian carcinomas and its potential as a marker for clear cell adenocarcinoma. Int J Gynecol Pathol. 2010; 29: 405-410.
141. Kotarski J, Marzec-Kotarska B, Szumio J, et al. [Expression of podoplanin in ovarian clear cell carcinoma]. Ginekol Pol. 2011; 82: 350-353.
142. Ordóñez NG. Application of immunohistochemistry in the diagnosis of epithelioid mesothelioma: a review and update. Hum Pathol. 2013; 44: 1-19.
143. Ordóñez NG. Value of PAX8, PAX2, claudin-4, and h-caldesmon immunostaining in distinguishing peritoneal epithelioid mesotheliomas from serous carcinomas. Mod Pathol. 2012. [Epub ahead of print].
144. Bassarova AV, Nesland JM, Davidson B. D2-40 is not a specific marker for cells of mesothelial origin in serous effusions. Am J Surg Pathol. 2006; 30: 878-882.
145. Tabrizi AD, Kalloger SE, Köbel M, et al. Primary ovarian mucinous carcinoma of intestinal type: significance of pattern of invasion and immunohistochemical expression profile in a series of 31 cases. Int J Gynecol Pathol. 2010; 29: 99-107.
146. Roy S, Chu A, Trojanowski JQ, et al. D2-40, a novel monoclonal antibody against the M2A antigen as a marker to distinguish hemangioblastomas from renal cell carcinomas. Acta Neuropathol. 2005; 109: 497-502.
147. Shibahara J, Kashima T, Kikuchi Y, et al. Podoplanin is expressed in subsets of tumors of the central nervous system. Virchows Arch. 2006; 448: 493-499.
148. Rivera AL, Takei H, Zhai J, et al. Useful immunohistochemical markers in differentiating hemangioblastoma versus metastatic renal cell carcinoma. Neuropathology. 2010; 30: 580-585.
149. Weinbreck N, Marie B, Bressenot A, et al. Immunohistochemical markers to distinguish between hemangioblastoma and metastatic clear-cell renal cell carcinoma in the brain: utility of aquaporin1 combined with cytokeratin AE1/AE3 immunostaining. Am J Surg Pathol. 2008; 32: 1051-1059.
150. Holt SC, Bruner JM, Ordoñez NG. Capillary hemangioblastoma. An immunohistochemical study. Am J Clin Pathol. 1986; 86: 423-429.
151. Hoang MP, Amirkhan RH. Inhibin alpha distinguishes hemangioblastoma from clear cell renal cell carcinoma. Am J Surg Pathol. 2003; 27: 1152-1156.
152. Jung SM, Kuo TT. Immunoreactivity of CD10 and inhibin alpha in differentiating hemangioblastoma of central nervous system from metastatic clear cell renal cell carcinoma. Mod Pathol. 2005; 18: 788-794.
153. Ordóñez NG. Value of PAX2 immunostaining in tumor diagnosis: a review and update. Adv Anat Pathol. 2012; 19: 401-409.
154. Shintaku M, Honda T, Sakai T. Expression of podoplanin and calretinin in meningioma: an immunohistochemical study. Brain Tumor Pathol. 2010; 27: 23-27.
155. Mishima K, Kato Y, Kaneko MK, et al. Podoplanin expression in primary central nervous system germ cell tumors: a useful histological marker for the diagnosis of germinoma. Acta Neuropathol. 2006; 111: 563-568.
156. Cho HY, Lee M, Takei H, et al. Immunohistochemical comparison of chordoma with chondrosarcoma, myxopapillary ependymoma, and chordoid meningioma. Appl Immunohistochem Mol Morphol. 2009; 17: 131-138.
157. Ishizawa K, Komori T, Shimada S, et al. Podoplanin is a potential marker for the diagnosis of ependymoma: a comparative study with epithelial membrane antigen (EMA). Clin Neuropathol. 2009; 28: 373-378.
158. Jokinen CH, Dadras SS, Goldblum JR, et al. Diagnostic implications of podoplanin expression in peripheral nerve sheath neoplasms. Am J Clin Pathol. 2008; 129: 886-893.
159. Huse JT, Pasha TL, Zhang PJ. D2-40 functions as an effective chondroid marker distinguishing true chondroid tumors from chordoma. Acta Neuropathol. 2007; 113: 87-94.
160. Sangoi AR, Dulai MS, Beck AH, et al. Distinguishing chordoid meningiomas from their histologic mimics: an immunohistochemical evaluation. Am J Surg Pathol. 2009; 33: 669-681.
161. Oakley GJ, Fuhrer K, Brachyury Seethala RR. SOX-9, and podoplanin, new markers in the skull base chordoma vs chondrosarcoma differential: a tissue microarray-based comparative analysis. Mod Pathol. 2008; 21: 1461-1469.
162. Daugaard S, Christensen LH, Hogdall E. Markers aiding the diagnosis of chondroid tumors: an immunohistochemical study including osteonectin, bcl-2, cox-2, actin, calponin, D2-40 (podoplanin), mdm-2, CD117 (c-kit), and YKL-40. APMIS. 2009; 117: 518-525.
163. Xu Y, Ogose A, Kawashima H, et al. High-level expression of podoplanin in benign and malignant soft tissue tumors: immunohistochemical and quantitative real-time RT-PCR analysis. Oncol Rep. 2011; 25: 599-607.
164. Allen CD, Okada T, Cyster JG. Germinal-center organization and cellular dynamics. Immunity. 2007; 27: 190-202.
165. Biddle DA, Ro JY, Yoon GS, et al. Extranodal follicular dendritic cell sarcoma of the head and neck region: three new cases, with a review of the literature. Mod Pathol. 2002; 15: 50-58.
166. Denning KL, Olson PR, Maley RH Jr, et al. Primary pulmonary follicular dendritic cell neoplasm: a case report and review of the literature. Arch Pathol Lab Med. 2009; 133: 643-647.
167. Lorenzi L, Lonardi S, Petrilli G, et al. Folliculocentric B-cell-rich follicular dendritic cells sarcoma: a hitherto unreported morphological variant mimicking lymphoproliferative disorders. Hum Pathol. 2012; 43: 209-215.
168. Ishida M, Kushima R, Okabe H. Immunohistochemical demonstration of D2-40 in basal cell carcinomas of the skin. J Cutan Pathol. 2008; 35: 926-930.
169. Misago N, Toda S, Narisawa Y. Tricholemmoma and clear cell squamous cell carcinoma (associated with Bowen's disease): immunohistochemical profile in comparison to normal hair follicles. Am J Dermatopathol. 2012; 34: 394-399.
170. Plaza JA, Ortega PF, Stockman DL, et al. Value of p63 and podoplanin (D2-40) immunoreactivity in the distinction between primary cutaneous tumors and adenocarcinomas metastatic to the skin: a clinicopathologic and immunohistochemical study of 79 cases. J Cutan Pathol. 2010; 37: 403-410.
171. Mahalingam M, Nguyen LP, Richards JE, et al. The diagnostic utility of immunohistochemistry in distinguishing primary skin adnexal carcinomas from metastatic adenocarcinoma to skin: an immunohistochemical reappraisal using cytokeratin 15, nestin, p63, D2-40, and calretinin. Mod Pathol. 2010; 23: 713-719.
172. Kaddu S, Leinweber B. Podoplanin expression in fibrous histiocytomas and cellular neurothekeomas. Am J Dermatopathol. 2009; 31: 137-139.
173. Bandarchi B, Ma L, Marginean C, et al. D2-40, a novel immunohistochemical marker in differentiating dermatofibroma from dermatofibrosarcoma protuberans. Mod Pathol. 2010; 23: 434-438.
174. Goldblum JR, Tuthill RJ. CD34 and factor-XIIIa immunoreactivity in dermatofibrosarcoma protuberans and dermatofibroma. Am J Dermatopathol. 1997; 19: 147-153.
175. Plaza JA, Ortega PF, Bengana C, et al. Immunolabeling pattern of podoplanin (d2-40) may distinguish basal cell carcinomas from trichoepitheliomas: a clinicopathologic and immunohistochemical study of 49 cases. Am J Dermatopathol. 2010; 32: 683-687.
176. Fernandez-Flores A. Podoplanin immunostaining in cutaneous apocrine carcinoma and in cutaneous metastasis from the breast. Appl Immunohistochem Mol Morphol. 2010; 18: 573-574.
177. Buonaccorsi JN, Plaza JA. Role of CD10, wide-spectrum keratin, p63, and podoplanin in the distinction of epithelioid and spindle cell tumors of the skin: an immunohistochemical study of 81 cases. Am J Dermatopathol. 2012; 34: 404-411.
178. Naito Y, Ishii G, Kawai O, et al. D2-40-positive solitary fibrous tumors of the pleura: diagnostic pitfall of biopsy specimen. Pathol Int. 2007; 57: 618-621.
179. Kreppel M, Scheer M, Drebber U, et al. Impact of podoplanin expression in oral squamous cell carcinoma: clinical and histopathologic correlations. Virchows Arch. 2010; 456: 473-482.
180. Inoue H, Miyazaki Y, Kikuchi K, et al. Podoplanin expression during dysplasia-carcinoma sequence in the oral cavity. Tumour Biol. 2012; 33: 183-194.
181. Rodrigo JP, García-Carracedo D, González MV, et al. Podoplanin expression in the development and progression of laryngeal squamous cell carcinomas. Mol Cancer. 2010; 9: 48.
182. Browning L, Bailey D, Parker A. D2-40 is a sensitive and specific marker in differentiating primary adrenal cortical tumours from both metastatic clear cell renal cell carcinoma and phaeochromocytoma. J Clin Pathol. 2008; 61: 293-296.
183. Wang SL, Li SH, Chen WT, et al. Expression of D2-40 in adjunct diagnosis of papillary thyroid carcinoma. APMIS. 2007; 115: 906-910.
184. Pusiol T, Zorzi MG, Morichetti D, et al. Malignant effusion of chromophobe renal-cell carcinoma: cytological and immunohistochemical findings. Diagn Cytopathol. 2012; 40: 56-61.
185. Tomita T. D2-40 immunocytochemical staining for pancreatic islets and pancreatic endocrine tumors. Pancreas. 2009; 38: 339-340.
186. Mohammed RA, Martin SG, Gill MS, et al. Improved methods of detection of lymphovascular invasion demonstrate that it is the predominant method of vascular invasion in breast cancer and has important clinical consequences. Am J Surg Pathol. 2007; 31: 1825-1833.
187. Gilchrist KW, Gould VE, Hirschl S, et al. Interobserver variation in the identification of breast carcinoma in intramammary lymphatics. Hum Pathol. 1982; 13: 170-172.
188. Yang Z, Adams AL, Hameed O. Attenuated podoplanin staining in breast myoepithelial cells: a potential caveat in the diagnosis of lymphatic invasion. Appl Immunohistochem Mol Morphol. 2009; 17: 425-430.